Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
Glaukos Corporation · NCT07400965
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 250
- US sites recruiting
- 1
- Study start
- December 5, 2025
- Record last updated
- February 27, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
Being studied: GLK-321 low dose BID; GLK-321 mid dose BID; GLK-321 high dose BID; GLK-321 high dose QD; Placebo BID
Conditions: Demodex Blepharitis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Signs of Demodex blepharitis in at least one eye
- Best Spectacle Corrected Visual Acuity (BSCVA) of 20/80 Snellen or better in each eye
Exclusion Criteria
- Presence of eczema or dermatitis in the ocular region of either eye
- Use of lid hygiene products within 14 days of Screening
- Active ocular infection or inflammation, other than blepharitis, in either eye at Screening
- Women who are pregnant, planning a pregnancy, or nursing
- Have used an investigational drug or device within 30 days prior to Screening or concurrently enrolled in another investigational drug or device trial
Recruiting US locations
Glaukos Clinical Study Site
Newport Beach, CA 92663
Site contact: Study Manager · 949-739-8749 · ClinicalResearch@Glaukos.com
Study contacts (from the official record)
- Study Manager · 949-739-8749 · ClinicalResearch@Glaukos.com